Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended 31st March 2005
Announcement Date: 28th April 2005
Accounting Basis: International Financial Reporting Standards (IFRS)
GSK reported a strong start to 2005, driven by growth in key pharmaceutical products and cost containment, despite headwinds from generic competition and manufacturing disruptions at its Cidra facility.
Key Financial Metrics
| Metric | Q1 2005 (£m) | Q1 2004 (£m) | Growth (CER%) |
|---|---|---|---|
| Turnover | 5,036 | 4,855 | 5% |
| Operating Profit | 1,747 | 1,493 | 18% |
| Profit Before Tax | 1,711 | 1,466 | 18% |
| Profit After Tax | 1,223 | 1,060 | 17% |
| Earnings Per Share (EPS) | 21.1p | 18.0p | 19% |
| Operating Margin | 34.7% | 30.8% | +3.9 pp |
| Net Debt | (1,505) | (2,003) | Improved |
| Cash & Equivalents | 2,774 | 1,526 | N/A |
Note: CER = Constant Exchange Rate. Net debt figures represent liabilities (negative values).
Material Changes vs. Prior Period
- Revenue Growth: Total turnover grew 5% (CER). Pharmaceutical sales rose 6% to £4.3 billion, while Consumer Healthcare sales grew 2% to £697 million.
- Profitability: Operating profit increased 18% (CER), outpacing revenue growth due to a 3% reduction in Selling, General & Administration (SG&A) costs and favorable sales mix.
- Product Performance:
- Growers: Seretide/Advair (+22%), Avandia/Avandamet (+25%), Lamictal (+30%), Valtrex (+28%), and Coreg (+50%).
- Decliners: Seroxat/Paxil (-43%) due to generic competition and supply issues; Wellbutrin (-23%) due to generic competition on IR/SR formulations.
- Regional Performance: US sales rose 4% (13% excluding generic/supply impacts). European sales grew 10%. International sales grew 5%.
- Balance Sheet: Net assets increased to £5,786 million. Net debt improved by £479 million to £1,505 million.
Guidance, Outlook, and Risks
Management Commentary and Guidance
CEO JP Garnier stated GSK is "on track to deliver our guidance of EPS growth in the low double-digit range" for 2005. The company expects the impact of generic competition to diminish as new products launch.
Pipeline and Launches
- Launched: Vesicare (over-active bladder) in the US; Boniva (osteoporosis) in the US.
- Upcoming: Requip (restless legs), Boostrix (vaccine), Entereg, and Fluarix expected in H2 2005.
- Key Assets: Cervarix (HPV vaccine) and Allermist (rhinitis) progressing well in Phase III.
Risks and Contingencies
- Manufacturing (Cidra): FDA halted distribution of Paxil CR and Avandamet due to quality issues. A Consent Decree was reached; re-supply expected mid-year. Potential penalties up to $10 million/year if terms are not met; a $650 million bond is required.
- Legal: Aggregate provision for legal disputes (excluding tax) is over £1 billion. Significant tax disputes with the IRS (claims totaling $7.6 billion including interest) are ongoing.
- Patent Litigation: Challenges to patents for Lamictal, Wellbutrin XL, and Requip are active. A securities class action regarding Paxil clinical data was filed in April 2005.
- Currency: Adverse currency impact of 2% on EPS due to a weaker US dollar, partially offset by a stronger Euro.
Investor Verification Checklist
- Cidra Resolution: Verify the timeline for re-supplying Paxil CR and Avandamet and the status of the $650 million bond requirement.
- Generic Impact: Monitor the trajectory of Wellbutrin XL sales growth to ensure it continues to offset losses from IR/SR formulations.
- Tax Litigation: Review updates on the IRS transfer pricing claims ($7.6 billion total exposure) and the admissibility of Advance Pricing Agreement (APA) evidence.
- Patent Expirations: Track outcomes of patent challenges for Lamictal (expires 2009) and Requip (compound patent expires 2007).
- Dividend Policy: Confirm the payment of the declared 10p interim dividend (payable 7th July 2005) and future buy-back activity under the £4 billion program.